Get the Stockscreener App
5.02
1.57%
-0.08
Alterity Therapeutics Ltd Adr stock is traded at $5.02, with a volume of 13,715.
It is down -1.57% in the last 24 hours and down -2.71% over the past month.
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
See More
Previous Close:
$5.10
Open:
$5.05
24h Volume:
13,715
Relative Volume:
0.18
Market Cap:
$77.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.0784
EPS:
-0.7092
Net Cash Flow:
-
1W Performance:
-4.38%
1M Performance:
-2.71%
6M Performance:
+23.04%
1Y Performance:
+280.30%
1-Day Range:
$4.95
$5.13
1-Week Range:
$4.895
$5.39
52-Week Range:
$1.001
$7.00
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Name
Alterity Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare ATHE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
5.02 | 77.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-25 | Downgrade | The Benchmark Company | Speculative Buy → Hold |
| Dec-12-24 | Initiated | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics announces ATH434 Phase 2 trial results - TipRanks
Alterity Therapeutics reports quarterly activities - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Most active stocks: US stocks with the highest trading volume today - Yahoo
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
Alterity Therapeutics LtdADR Shares Close the Week 40.3% HigherWeekly Wrap - Nasdaq
Most Volatile Stocks, What Investors Need to Know - MarketBeat
A Full List of Australia ADRs - Investing.com Australia
How Investors Can Identify and Successfully Trade Gap-Down Stocks - MarketBeat
What Investors Need to Know to Beat the Market - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
Alterity Therapeutics Ltd Adr Stock (ATHE) Financials Data
There is no financial data for Alterity Therapeutics Ltd Adr (ATHE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):